NCT02939794View on ClinicalTrials.gov

The Effect of Ferric Carboxymaltose on Hemoglobin and Blood Transfusion in Cardiac Surgery

PHASE4UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2019

Conditions
Anemia
Interventions
DRUG

Ferinject

1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery

DRUG

Placebo

Saline (normal saline, sodium chloride)

Sponsors

Collaborators (1)

Carmel Medical Center
All Listed Sponsors
collaborator

Carmel Medical Center

OTHER

collaborator

The Baruch Padeh Medical Center, Poriya

OTHER_GOV

lead

Rambam Health Care Campus

OTHER

NCT02939794 - The Effect of Ferric Carboxymaltose on Hemoglobin and Blood Transfusion in Cardiac Surgery | Biotech Hunter | Biotech Hunter